Andrew Scott serves as the Director, Strategic Alliances & Issue Advocacy within Bristol Myers Squibb’s US Policy & Government Affairs in Washington, DC. Focusing on hematology and oncology, Andrew prioritizes mutual value creation, thinking of health systems holistically, and collaborating with diverse stakeholders to advance public policies that improve patient access and affordability, and protect innovation.
Before BMS, he served as Vice President of Policy & Public Affairs at Global Liver Institute (GLI), leading the organization’s efforts to elevate the patient voice, and shape public policy to address the unmet need of patients impacted by liver disease. Before GLI, he acted as Senior Federal Affairs Director at Cullari Communications Global, a public affairs advocacy firm, where he provided clients with surround sound advocacy campaign support at the state and federal level. He got his start in health policy and government affairs at Endo Pharmaceuticals, serving as the company’s principal federal lobbyist. Andrew received his Master of Business Administration from the University of North Carolina’s Kenan-Flagler Business School in 2022.
Before BMS, he served as Vice President of Policy & Public Affairs at Global Liver Institute (GLI), leading the organization’s efforts to elevate the patient voice, and shape public policy to address the unmet need of patients impacted by liver disease. Before GLI, he acted as Senior Federal Affairs Director at Cullari Communications Global, a public affairs advocacy firm, where he provided clients with surround sound advocacy campaign support at the state and federal level. He got his start in health policy and government affairs at Endo Pharmaceuticals, serving as the company’s principal federal lobbyist. Andrew received his Master of Business Administration from the University of North Carolina’s Kenan-Flagler Business School in 2022.
Speaking In
1:00 PM - 2:00 PM
Tuesday, October 24